<DOC>
	<DOCNO>NCT00698893</DOCNO>
	<brief_summary>The purpose study evaluate safety reactogenicity candidate gD vaccine , without MPL , HSV-seropositive subject . The immune response elicit subject also evaluate .</brief_summary>
	<brief_title>Evaluation Safety Candidate gD Vaccine , With Without MPL Healthy Herpes Simplex Virus-Positive Adults</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Between 18 40 year age Seropositive antibody HSV Female volunteer must use contraceptive least 2 month entry avoid become pregnant duration study . Good physical condition establish physical examination history take time entry Any abnormal laboratory value among test perform screen . History persistent hepatic , renal , cardiac respiratory disease Clinical sign acute illness time entry study . Previous history asthma hypersensitivity drug . Seropositive antibody human immunodeficiency virus Pregnancy lactation . Treatment corticosteroid immunomodulating drug . Simultaneous participation another clinical trial . Administration vaccine immunoglobulin study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Herpes simplex</keyword>
	<keyword>Herpes simplex candidate ( gD ) vaccine</keyword>
</DOC>